BioLineRx's CXCR4 Antagonist: Promising For Stem Cell Mobilization And AML

Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.